Mini-Focus Issue: MRAs and DiureticsClinical ResearchReal World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure: A U.S. Center’s Experience
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
Supported by U.S. National Institutes of Health grants K23HL114868, L30HL115790, R01HL139629, R21HL143092, R01HL128973 (to J.M.T.); R01DK113191 and P30DK079210 (to Dr. Wilson); and 5T32HL007950 (to Dr. Griffin). Dr. Riello is a consultant for Janssen, Johnson & Johnson, Portola, Medicure, and AstraZeneca. Dr. Coca is a consultant for RenalytixAI, CHF Solutions, Takeda, and Bayer; and has equity in RenalyitxAI. Dr. Testani has received research funding from Sequana Medical, 3ive Labs, Cardionomic, Bayer, Boehringer Ingelheim, MagentaMed, Otsuka, Sanofi, FIRE1, and Abbott; and is a consultant for Bristol-Myers Squibb AstraZeneca, Novartis, 3ive Labs, Cardionomic, Bayer, Boehringer Ingelheim, MagentaMed, Reprieve Medical, Sanofi, FIRE1, and W.L. Gore. Dr. Tang has received consulting fees for Sequana. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- ∗
Drs. Griffin and Soufer are joint first authors.